logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Intellia Therapeutics, Inc.


USPTO Granted Patents = 20


Forward Citations = 16

Loading Chart...
Loading Chart...

40 inventors (with patents filed for the assignee):

goldMedal Walter R Strapps (8 out of 21 patents)

silverMedal Shobu Odate (7 out of 7 patents)

bronzeMedal Reynald Michael Lescarbeau (6 out of 6 patents)

4.  Jessica Lynn Seitzer (5 out of 5 patents)

5.  Yi Yang (4 out of 5 patents)

6.  Amy Madison Rhoden Smith (4 out of 4 patents)

7.  David Morrissey (3 out of 12 patents)

8.  Craig Stephen Mickanin (3 out of 4 patents)

9.  Christian Dombrowski (3 out of 3 patents)

10.  Arti Mahendra Prakash Kanjolia (3 out of 3 patents)

11.  Morag Helen Stewart (2 out of 9 patents)

12.  Jennifer Snead (2 out of 2 patents)

13.  Christian Schmedt (2 out of 3 patents)

14.  Susan C Stevenson (2 out of 4 patents)

15.  Sarah Beth Hesse (2 out of 2 patents)


20 patents:

1. 12735698 - Modified Guide RNAs (2026-09-15),
2. 12686876 - Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent (2026-07-21),
3. 12674151 - Compositions and methods for kallikrein (KLKB1) gene editing (2026-07-07),
4. 12630820 - Compositions and Methods for Immunotherapy (2026-05-19),
5. 12559748 - COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES (2026-02-24),
6. 12480109 - Compositions and methods for kallikrein (KLKB1) gene editing (2025-11-25),
7. 12460205 - Compositions and methods for treating alpha-1 antitrypsin deficiency (2025-11-04),
8. 12391722 - Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA) (2025-08-19),
9. 12214023 - Compositions and methods for expressing factor IX (2025-02-04),
10. 12173284 - Modified guide RNAs (2024-12-24),
11. 12077483 - Modified amine lipids (2024-09-03),
12. 12037583 - Compositions and methods for immunooncology (2024-07-16),
13. 11965165 - Compositions and methods for TTR gene editing and treating ATTR amyloidosis (2024-04-23),
14. 11851659 - Compositions and methods for immunooncology (2023-12-26),
15. 11795460 - Compositions and methods for TTR gene editing and treating ATTR amyloidosis (2023-10-24),
Company Overview
Intellia Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of innovative therapies using CRISPR gene editing technology. The company focuses on harnessing the potential of this groundbreaking approach to treat a range of genetic diseases and conditions. Intellia's research encompasses various therapeutic areas, including hematology, immunology, and oncology, aiming to create transformative treatments that address unmet medical needs and improve patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

20 Patents

#138 in

#16,409 in

#31,295 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Intellia Therapeutics, Inc.

Forward Citations = 16

40 inventors:

goldMedal Walter R Strapps (8 out of 21 patents)

silverMedal Shobu Odate (7 out of 7 patents)

bronzeMedal Reynald Michael Lescarbeau (6 out of 6 patents)

4.  Jessica Lynn Seitzer (5 out of 5 patents)

5.  Yi Yang (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Intellia Therapeutics, Inc.. Retrieved from https://idiyas.com/company/intellia-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…